Serum concentration and urinary excretion of the luteinizing hormone-releasing hormone agonist buserelin in patients with endometriosis

Ludwig Kiesel, L Kiesel, Kiesel L, J. Sandow, Sandow J, Jürgen Sandow, Bertges K, Karin Bertges, K Bertges, G. Jerabek-Sandow, Jerabek-Sandow G, HEIDRUN TRABANT, Trabant H, H Trabant, Runnebaum B, B. Runnebaum
The Journal of clinical endocrinology and metabolism · 1989 · vol. 68(6) , pp. 1167–1173 · doi:10.1210/jcem-68-6-1167 · PMID:2498387 · W1992956185
Other OA: closed CC0 ⤵ 4 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-09 ⓘ

This study characterized the pharmacokinetics of buserelin in women with endometriosis, finding that intact buserelin and a specific pentapeptide metabolite were present in serum and urine, with initial hormonal surges following administration.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

We studied the pharmacokinetics of iv and intranasally administered buserelin, a LHRH agonist peptide, in 14 women with endometriosis. Serum and urinary buserelin concentrations were determined by specific RIA (buserelin antiserum AS-639). Intact buserelin and the metabolites in urine were separated by reverse phase high performance liquid chromatography and measured by RIA. The mean serum buserelin concentrations were 101 +/- 33 (+/- SD) ng/mL 20 min and 1.12 +/- 0.12 ng/mL 360 min after its iv injection in 6 women, and the mean elimination half-life between 20 and 360 min was 51 min. In serum, intact buserelin was the main constituent (10 min, 90%; 120 min, 74%; 360 min, 52%), and the major metabolite was the buserelin-(5-9) pentapeptide (10 min, 0.6%; 120 min, 19%; 360 min, 12%). In the urine collected 0-1 h after buserelin administration, intact buserelin was 66% and the 5-9 pentapeptide was 28% of the total excretion. In the urine collected between 6-24 h after buserelin administration, intact buserelin accounted for 67% and the 5-9 pentapeptide for 32% of the total excretion. The urinary buserelin concentration was 1345 +/- 156 micrograms/g creatinine 1 h and 25 +/- 5 micrograms/g creatinine 6-24 h after buserelin administration. Serum LH, FSH, and estradiol concentrations increased acutely up to 10-fold above basal values; the mean peak LH, FSH, and estradiol values occurred at 180-240 min, 240 min, and 24 h, respectively. In therapeutic studies with buserelin nasal spray in 5 women, serum concentrations of 0.9-1.4 ng/mL were found 15 min after a single dose of 300 micrograms, intranasally, and the urinary excretion was 2.52-3.68 micrograms/24 h during daily administration of 3 doses of 300 micrograms at intervals of 8 h. These results confirm that buserelin is slowly inactivated and remains available to pituitary receptors for a prolonged period after its iv or intranasal administration.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Buserelin Endometriosis Gonadotropin-Releasing Hormone Administration, Intranasal Administration, Intranasal Adult Adult Biological Availability Biological Availability Buserelin Buserelin Buserelin Buserelin Buserelin Chromatography, High Pressure Liquid Chromatography, High Pressure Liquid Endometriosis Endometriosis Female Female

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (2)

Cited by (4)

References (14)

Cited by (4)

Source provenance

europepmc
last seen: 2026-10-22T06:08:12.857683+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T21:14:02.509446+00:00
License: CC0 · commercial use OK